sport

hub / index

advocacy

UCI

UCI 100
COMMUNIQUE DE PRESSE / PRESS RELEASE - Lausanne, SUI - 21 July 1999
Information on UCI anti-doping controls is based on two principles:
  • in the event of a positive result confirmed during a stage race, the information is given firstly to the rider and his team, and then to the media;
  • in the event of a positive result caused by medical treatment (to which every rider is entitled!), the UCI sees to it that medical secrecy is fully respected, ensuring that the data in question is kept confidential.
We confirm that the controls performed up to 19th July during the Tour de France have all produced negative results.

Without prejudice to the medical secrecy which the UCI fully wishes to maintain, but at the express request of Lance Armstrong and his team, taking into account the exceptional situation brought about by certain publications, the UCI is making an exception to this principle by confirming that:

the rider used the ointment Cemalyt (which contains triamcinolone) to treat a skin allergy.
The medical prescription has been shown to the UCI. The rider was tested on 3rd July 1999 after the prologue, and the result was negative, with no trace of corticosteroids. The rider was tested again on 4th July, and on this occasion minute traces were detected. The result of the tests on these two dates unquestionably demonstrate that there was no systematic use.

The UCI recalls that the use of corticosteroids is restricted as follows in the IOC/UCI list:

Figure III Classes of drugs subject to certain restrictions

C : The use of corticosteroids is prohibited, except when used for topical application (auricular, opthalmological or dermatological), inhalations (asthma and allergic rhinitis) and local or intra-articular injections. Such forms of utilisation are to be proved by the rider with a medical prescription.
In view of all these elements, the UCI, after discussing the case with the competent French authorities, affirms in the strongest terms that such use is permitted by the rules, and therefore does not constitute any form of doping.

We should like to ask all press representatives to be aware of the complexity of doping issues and the related aspects of the rules and the law before producing their publications.

This will allow considerations of a rather superficial, not to say unfounded nature to be avoided. It is indeed surprising to read that testosterone/epitestosterone ratios are used to indicate the concentration of corticosteroids.

We are often faced with questionable conclusions which damage the integrity of the riders who, it should not be forgotten, have rights too.

UCI Press Office

19990721


News